← Compound index
RESEARCH FAMILY / NGF-MIMETICS

NGF mimetics: GK & GTS seriesМиметики ФРН

A family of experimental peptides designed from exposed loops of nerve growth factor. Related structures can differ in cell survival, differentiation and pain responses.

CognitionRecovery
Source linked

What the studies found

Animal research · 2011

Neuroprotective effect of GK-2, a dipeptide mimetic of nerve growth factor, during experimental focal ischemia in middle cerebral artery basin

GK-2 reduced infarct area and improved neurological tests.

Study notes · methods, sources and limitations

Participants or model Rats with focal cerebral ischemia after middle cerebral artery occlusion

Important limitations

  • Animal-only finding; human stroke benefit and safety are unestablished.

Bulletin of experimental biology and medicine · PMID 22462051 · Indexed abstract

Original source or citation ↗

Study results and tables ↗

Animal research · 2018

An experimental evaluation of the therapeutic window of the neuroprotective activity of a low-molecular nerve growth factor mimetic GK-2

GK-2 reduced infarct volume with experimental treatment starts between four and 24 hours after injury.

Study notes · methods, sources and limitations

Participants or model Rat transient middle cerebral artery occlusion; treatment-start timing experiment

Important limitations

  • An animal treatment window cannot be used as a human treatment window. No human clinical outcome was measured.

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · PMID 30132457 · Indexed abstract

Original source or citation ↗

Study results and tables ↗

Animal research · 2015

Dimeric dipeptide mimetics of the nerve growth factor Loop 4 and Loop 1 activate TRKA with different patterns of intracellular signal transduction.

GK-2 and GK-6 both increased TrkA phosphorylation, but GK-6 additionally recruited ERK, promoted PC12 differentiation and lowered rat pain thresholds. GK-2 favored AKT signaling in these assays and did not produce the same hyperalgesia.

Study notes · methods, sources and limitations

Participants or model HT-22 and PC12 cells; rat tail-flick experiments

Important limitations

  • Preclinical findings do not establish human benefit or safety. Abstract only. Full methods and independent replication remain unconfirmed.

Journal of biomedical science · Indexed abstract

Original source or citation ↗

Study results and tables ↗
01 / OVERVIEW

About NGF mimetics: GK & GTS series

Names in this research collection

GK-1 · GK-2 · GK-2a · GK-2b · GK-2c · GK-2d · GK-2e · GK-2w · GK-2f · GK-3 · GK-4 · GK-5 · GK-6 · GK-7 · GK-8 · GTS-113 · GTS-115 · TrkA

Compound class
Peptide research family
Research collection
Neuropeptide research · editorial grouping
Institutions in linked studies
See individual study records
Source review
Review dates and the material assessed are listed with each publication below.
02 / HOW TO READ THE RESEARCH

Understanding the evidence

Human research

No human treatment trial assessed for this family

Study methods

Member-specific studies; patents and archival leads identified separately

Independent replication

Independent replication not established by the records collected here

Source access

Primary abstracts, selected full texts, patents and explicit retrieval targets

Safety evidence

Cell and animal effects do not establish human safety; analogues may differ

Open a topic for the evidence assessment.

More findings, background and history
IDENTITY / MEMBER-SPECIFIC EVIDENCE

Inside this research family

Grouping supports navigation. It does not imply equivalent composition, mechanisms, effectiveness or safety.

Research objects, findings and source boundaries
MemberIdentityWhat the source supports
GK-2 / GK-6NGF loop 4 / loop 1 dimeric mimetics

Both activated TrkA. GK-6 additionally recruited ERK, induced differentiation and produced hyperalgesia in the 2015 experiments.

Dimeric dipeptide mimetics of the nerve growth factor Loop 4 and Loop 1 activate TRKA with different patterns of intracellular signal transduction. ↗

GK-1; GK-2a/b/c/d/e/wLoop 4 patent series

Monomer, linker and residue variants; activity cannot be inherited from GK-2.

Dipeptide mimetics of NGF and BDNF neurotrophins — US9683014B2 ↗

GK-3–GK-8Loop 1 patent series

Includes GABA-containing GK-7/GK-8 structures. This alone does not establish GABA-receptor activity.

Dipeptide mimetics of NGF and BDNF neurotrophins — US9683014B2 ↗

GTS-113 / GTS-115NGF loop 3 mimetics

GTS-115 combined laboratory protection with differentiation and pain-sensitivity effects.

Design, synthesis, and neuroprotective effects of a dimeric dipeptide mimetic of the third loop of the nerve growth factor ↗

GK-2fUnresolved code

Appears in patent biological prose; a reliable structure-to-code mapping remains to be recovered.

Dipeptide mimetics of NGF and BDNF neurotrophins — US9683014B2 ↗

Interpretation and open questions

A family card keeps the analogue library visible without giving sparsely documented codes the appearance of established drugs.

Signaling depends on assay and timing. “AKT only” is not a universal description: later work also reports PLCγ recruitment for GK-2.

Explore the Russian peptide research map ↗

Stroke research matrix ↗ — compare human stroke outcomes, experimental findings, safety and adjacent cerebral-ischemia research.

What remains unclear

The available experimental studies leave human benefit and safety uncertain.

No human intervention report has been identified among the linked records; unclassified archival leads may remain. Several publications can describe the same participants.

Browse original study records ↗
PATENT RESEARCH / COLLECTION UPDATED 7 NOVEMBER 2026

Patents and claimed inventions

These 1 grouped records distinguish claimed molecules, uses, formulations and related chemistry. Patent disclosure does not establish clinical benefit or approval.

2017 · US9683014B2 · Dipeptide mimetics of NGF and BDNF neurotrophins — US9683014B2Platform context · GSB-106 and imipramine reduced immobility; GBK-201 and GBK-108 increased it

Findings described in words

Experimental effects differ by candidate: some dimers were protective or antidepressant-like, while some monomers had unfavorable effects.

BDNF-model behavior
GSB-106 and imipramine reduced immobility; GBK-201 and GBK-108 increased itDifferent molecules; the unfavorable direction is retained
Candidate identity and viability
Some monomeric mimetics reduced neuronal viability; dimeric results were more favorableCandidate-specific findings, not a class-wide clinical effect
All reported results, comparisons and limitations →

Platform context. The title refers to NGF and BDNF mimetics, but the granted US claims specifically identify a Ser-Lys-based dimer. This is not a grant to every GK, GSB, GBK or GTS candidate.

A patent disclosure is not clinical proof, marketing approval or a legal opinion. Related publications and patent family members may describe the same experiments.

Publication
US9683014B2 ↗ · 2017-06-20
Earliest priority / filing
2009-02-16 / 2014-08-15
Original applicant / assignee
Uchrezhdenie Rossiiskoi Akademii Meditsynskikh Nauk Nauchno-Issledovatelsky Institut Farmakologii Imeni Vvzakusova Ramn
Indexed status
Expired - Fee Related · checked 2026-11-06
Patent family
42561958 · family publications are related filings, not independent studies.
Original title, inventors and related publications

Dipeptide mimetics of NGF and BDNF neurotrophins

Inventors: Sergey Borisovich Seredenin; Alexandrovna Tatyana GUDASHEVA.

US9683014B2 · US20110312895A1 · EP2397488B1 · CN102365294B · RU2410392C2 · WO2010093284A1

Original patent PDF ↗

Read source review →

Status is an indexed snapshot, not an official legal assessment. Search the patent collection and read the method →

03 / SOURCE RECORDS

Findings by study

Explore related research ↗

Animal research · 2011

Neuroprotective effect of GK-2, a dipeptide mimetic of nerve growth factor, during experimental focal ischemia in middle cerebral artery basin

GK-2 reduced infarct area and improved neurological tests.

Study notes and original source
2011Animal / experimentalEnglish abstract

Neuroprotective effect of GK-2, a dipeptide mimetic of nerve growth factor, during experimental focal ischemia in middle cerebral artery basin

Seredenin SB, Silachev DN, Gudasheva TA, Pirogov YA, Isaev NK · Bulletin of experimental biology and medicine · PMID 22462051

GK-2 reduced infarct area and improved neurological tests.

Population / setting
Rats with focal cerebral ischemia after middle cerebral artery occlusion
Source reviewed
Indexed citation and abstract reviewed via Europe PMC / PubMed; full methods and risk of bias not comprehensively appraised.
Study limitations
  • Animal-only finding; human stroke benefit and safety are unestablished.

Reviewed 2026-10-05.

Read the source ↗

Animal research · 2018

An experimental evaluation of the therapeutic window of the neuroprotective activity of a low-molecular nerve growth factor mimetic GK-2

GK-2 reduced infarct volume with experimental treatment starts between four and 24 hours after injury.

Study notes and original source
2018Animal / experimentalEnglish abstract

An experimental evaluation of the therapeutic window of the neuroprotective activity of a low-molecular nerve growth factor mimetic GK-2

Seredenin SB, Povarnina PY, Gudasheva TA · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · PMID 30132457

GK-2 reduced infarct volume with experimental treatment starts between four and 24 hours after injury.

Population / setting
Rat transient middle cerebral artery occlusion; treatment-start timing experiment
Source reviewed
Indexed citation and abstract reviewed via Europe PMC / PubMed; full methods and risk of bias not comprehensively appraised.
Study limitations
  • An animal treatment window cannot be used as a human treatment window.
  • No human clinical outcome was measured.

Reviewed 2026-10-05.

Read the source ↗

Animal research · 2015

Dimeric dipeptide mimetics of the nerve growth factor Loop 4 and Loop 1 activate TRKA with different patterns of intracellular signal transduction.

GK-2 and GK-6 both increased TrkA phosphorylation, but GK-6 additionally recruited ERK, promoted PC12 differentiation and lowered rat pain thresholds. GK-2 favored AKT signaling in these assays and did not produce the same hyperalgesia.

Study notes and original source
2015Animal / experimentalEnglish abstract

Dimeric dipeptide mimetics of the nerve growth factor Loop 4 and Loop 1 activate TRKA with different patterns of intracellular signal transduction.

Gudasheva TA, Povarnina PY, Antipova TA, Firsova YN, Konstantinopolsky MA, Seredenin SB · Journal of biomedical science

GK-2 and GK-6 both increased TrkA phosphorylation, but GK-6 additionally recruited ERK, promoted PC12 differentiation and lowered rat pain thresholds. GK-2 favored AKT signaling in these assays and did not produce the same hyperalgesia.

Population / setting
HT-22 and PC12 cells; rat tail-flick experiments
Source reviewed
Primary publication metadata and indexed abstract checked via Europe PMC; full methodological review pending.
Study limitations
  • Preclinical findings do not establish human benefit or safety.
  • Abstract only. Full methods and independent replication remain unconfirmed.

Reviewed 2026-10-05.

Read the source ↗

Review of earlier studies · 2018

Novel Technologies for Dipeptide Drugs Design and their Implantation.

The developers distinguish drug-inspired peptide design (Noopept and Dilept) from mimicking peptide/protein turns (GB-115 and GK-2). This is a historical design framework, not evidence of a shared clinical effect.

Study notes and original source
2018ReviewEnglish abstract

Novel Technologies for Dipeptide Drugs Design and their Implantation.

Gudasheva TA, Ostrovskaya RU, Seredenin SB · Current pharmaceutical design

The developers distinguish drug-inspired peptide design (Noopept and Dilept) from mimicking peptide/protein turns (GB-115 and GK-2). This is a historical design framework, not evidence of a shared clinical effect.

Population / setting
Developer account of medicinal-chemistry programs
Source reviewed
Primary publication metadata and indexed abstract checked via Europe PMC; full methodological review pending.
Study limitations
  • Developer review; claims require appraisal of each original study.
  • A shared design method does not establish equivalent biology or clinical benefit.

Reviewed 2026-10-05.

Read the source ↗

Experiment described in a patent · 2017

Dipeptide mimetics of NGF and BDNF neurotrophins — US9683014B2

The description enumerates NGF and BDNF analogue series, but the granted US claims specifically identify a Ser-Lys-based dimer rather than every named candidate. GK-1/GK-2 and GSB-104 experiments remain preclinical and include identity or outcome ambiguities.

Study notes and original source
2017Patent / reported experimentsFull text available

Dipeptide mimetics of NGF and BDNF neurotrophins — US9683014B2

· Primary source linked above

The description enumerates NGF and BDNF analogue series, but the granted US claims specifically identify a Ser-Lys-based dimer rather than every named candidate. GK-1/GK-2 and GSB-104 experiments remain preclinical and include identity or outcome ambiguities.

Results and tables

Reported patent results

Findings described in words

Experimental effects differ by candidate: some dimers were protective or antidepressant-like, while some monomers had unfavorable effects.

Large NGF/BDNF-mimetic patent program with numerous cell and animal comparisons; the granted US claims are narrower than the experimental catalogue.

Population or model Patent chemistry and preclinical examples

Results · Selected neuronal-viability examples and final Porsolt comparisons, Figures 2.12–2.13.
MeasureResultComparison, timing and statistics
BDNF-model behaviorGSB-106 and imipramine reduced immobility; GBK-201 and GBK-108 increased itDifferent molecules; the unfavorable direction is retained
Candidate identity and viabilitySome monomeric mimetics reduced neuronal viability; dimeric results were more favorableCandidate-specific findings, not a class-wide clinical effect
Reporting conflictGSB-104 descriptions and GK-2f structure mapping require reconciliationNo single pooled efficacy percentage inferred from inconsistent examples

The title and broad description do not mean every experimental candidate is within the granted claims. Cell survival and behavioral proxies do not establish clinical antidepressant or neuroregenerative efficacy.

Source for these results ↗ · Reviewed 2026-11-06

Population / setting
Patent chemistry and preclinical examples
Source reviewed
Selected original-source text checked; full methodological review pending.
Study limitations
  • Patent proposals are not established clinical uses.
  • Resolve code/structure ambiguities and assay-specific contradictions before interpreting activity.

Reviewed 2026-11-06.

Read the source ↗

Animal research · 2017

Design, synthesis, and neuroprotective effects of a dimeric dipeptide mimetic of the third loop of the nerve growth factor

GTS-113 and GTS-115 were designed from NGF loop 3. GTS-115 showed cell protection and reduced infarct volume in a rat stroke model, but also induced hyperalgesia.

Study notes and original source
2017Animal / experimentalEnglish abstract

Design, synthesis, and neuroprotective effects of a dimeric dipeptide mimetic of the third loop of the nerve growth factor

· Primary source linked above

GTS-113 and GTS-115 were designed from NGF loop 3. GTS-115 showed cell protection and reduced infarct volume in a rat stroke model, but also induced hyperalgesia.

Population / setting
Cultured cells and rat ischemia/pain models
Source reviewed
Selected original-source text checked; full methodological review pending.
Study limitations
  • Publisher abstract reviewed; full methods pending.
  • Animal efficacy and pain responses do not establish human benefit or safety.

Reviewed 2026-10-05.

Read the source ↗

Animal research · 2022

Antidepressant-like Effects of BDNF and NGF Individual Loop Dipeptide Mimetics Depend on the Signal Transmission Patterns Associated with Trk

GSB-106 showed acute antidepressant-like activity; GSB-214 also became active with repeated administration. GTS-201 was inactive in this forced-swim comparison. Different signaling patterns did not yield interchangeable behavioral effects.

Study notes and original source
2022Animal / experimentalFull text available

Antidepressant-like Effects of BDNF and NGF Individual Loop Dipeptide Mimetics Depend on the Signal Transmission Patterns Associated with Trk

· Primary source linked above

GSB-106 showed acute antidepressant-like activity; GSB-214 also became active with repeated administration. GTS-201 was inactive in this forced-swim comparison. Different signaling patterns did not yield interchangeable behavioral effects.

Population / setting
Rodent forced-swim tests; comparison with cell-signaling results
Source reviewed
Selected original-source text checked; full methodological review pending.
Study limitations
  • Behavioral proxies are not a clinical diagnosis or treatment outcome.
  • Different schedules and models limit cross-compound comparisons.

Reviewed 2026-10-05.

Read the source ↗

Follow shared publications or research classes. These links do not establish equivalent effects between compounds.

Research collection curated by @PepMariner · editorial standards. Send a source correction ↗

Browse bibliography & PDFs ↗